financetom
Business
financetom
/
Business
/
Cadre Q4 EPS, Net Sales Increase
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cadre Q4 EPS, Net Sales Increase
Mar 11, 2025 1:44 PM

04:23 PM EDT, 03/11/2025 (MT Newswires) -- Cadre (CDRE) reported Q4 earnings Tuesday of $0.32 per diluted share, up from $0.25 a year earlier.

Analysts polled by FactSet expected $0.46.

Net sales for the quarter ended Dec. 31 were $176 million, up from $124.6 million a year earlier.

Analysts surveyed by FactSet expected $170.9 million.

The company expects full year 2025 net sales between $572 million and $601 million.

Analysts polled by FactSet expect $621.8 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
UiPath Unusual Options Activity For May 31
UiPath Unusual Options Activity For May 31
May 31, 2024
Investors with a lot of money to spend have taken a bullish stance on UiPath ( PATH ) . And retail traders should know. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know. But when something this big...
Salesforce's Start to Fiscal Year 2025 'Rocky,' Macquarie Says
Salesforce's Start to Fiscal Year 2025 'Rocky,' Macquarie Says
May 31, 2024
11:15 AM EDT, 05/31/2024 (MT Newswires) -- Salesforce ( CRM ) experienced a rocky start to fiscal year 2025, Macquarie said Friday in a note to clients, but added it still sees the company as well positioned to benefit from digital transformations. The firm noted that the company's stock has fallen about 18% after its fiscal Q1 results, mainly due...
Ocugen Gets Recommendation For Dose Escalation in Eye Disease Trial; Shares Climb
Ocugen Gets Recommendation For Dose Escalation in Eye Disease Trial; Shares Climb
May 31, 2024
11:16 AM EDT, 05/31/2024 (MT Newswires) -- Ocugen ( OCGN ) said Friday the Data and Safety Monitoring Board has recommended to proceed with dose escalation in the trial of OCU410, its potential therapy for geographic atrophy, an advanced stage of dry age-related macular degeneration. The DSMB has recommended to proceed with dosing subsequent GA subjects with the high dose...
What's Going On With PENN Entertainment Stock Friday?
What's Going On With PENN Entertainment Stock Friday?
May 31, 2024
PENN Entertainment, Inc. ( PENN )  shares are trading higher on Friday. The company’s shareholder, Donerail Group, sent a letter to the company’s Board saying the company could get ‘up to double its current trading price in the event of a sale.’ Donerail Group, in a statement, said the company’s misguided interactive strategy and poor capital allocation have affected shareholder...
Copyright 2023-2026 - www.financetom.com All Rights Reserved